Package leaflet: Information for the user TAKHZYRO 300 mg solution for injection in pre-filled syringe lanadelumab This medicin
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TAKHZYRO® safely and ef
![Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States | Business Wire Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States | Business Wire](https://mms.businesswire.com/media/20220418005108/en/1247790/23/Takeda_Red_Logo_2021.jpg)
Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States | Business Wire
![TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for HAE Patients in the United States - HAE International (HAEi) TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for HAE Patients in the United States - HAE International (HAEi)](https://haei.org/wp-content/uploads/2020/11/news_takeda.jpg)